BD, a maker of syringes, needles, infusion pumps and other medical products, said it will invest a total of $19 billion in the U.S. over several years. The pact includes investments in U.S. manufacturing, innovation and end-to-end production capabilities, the company said.
The agreement provides relief from any future tariffs on BD products under Section 232, subject to BD achieving undisclosed milestones.
Under the agreement, the company said it will spend $3 billion to expand strategic production sites across the country and increase its annual U.S. output by about 5 billion essential medical consumables. The expansion is expected to boost BD’s share of domestically supplied essential medical technology to about 80%.
BD also agreed to make all of its needles used in the U.S. with American-made steel.
Read the article.